A First-In- Human Phase 1/1b Multicenter, Open-Label Dose Escalation Study To Assess Safety And Tolerability Of Pmd-026, A First-In-Class Oral Rsk Inhibitor, In Metastatic Breast Cancer Patients
CANCER RESEARCH（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要